

Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. *Blood Adv.* 2022;6(21):5774-5785.

On page 5780, in the legend for Figure 2C, the estimated progression-free survival at 48 months should read 70%, not 80%.

---

<https://doi.org/10.1182/bloodadvances.2023011694>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](#), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.